Mr. Lapalme has over the course of his career held numerous senior management positions in various global life sciences companies. He is former Senior Vice-President, Sales and Marketing for Ciba-Geigy (which subsequently became Novartis) and former Chief Executive Officer and Chairman of the Board of Rhone-Poulenc Pharmaceuticals Inc. in Canada and in North America, as well as Executive Vice-President and Chief Executive Officer of Rhone-Poulenc-Rorer Inc. North America (now Sanofi-Aventis), where he supervised the development, manufacturing and sales of prescription products in North and Central America. Mr. Lapalme served on the Board of the National Pharmaceutical Council USA and was a Board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting patent protection for pharmaceuticals. Until recently, he was Board member and Chairman of the Board of Sciele Pharma Inc. which was acquired by Shionogi and Co. Ltd. Mr. Lapalme is currently Chairman of the Board of Biomarin Inc., Chairman of the Board of Pediapharm Inc., Board member of Algorithme Pharma Inc. and Insy's Therapeutics Inc., a Phoenix Arizona based specialty pharma Co. He studied at the University of Western Ontario and at INSEAD, France.
Mr. Pastor Is an economist by training with a master’s degree from the University of Montreal. Prior to CTI he worked for Merrill Lynch Canada in charge of all Quebec based company debt issuers. He also worked at the Federation des Caisses Desjardins as a portfolio manager. Partner at CTI Capital Group since 1989, Mr Pastor is currently in charge of business development. As General Partner of CTI Life Sciences Funds, he is responsible for the management and administration of the Fund. Mr. Pastor is currently a board member of the CQDM (Quebec Consortium for Drug Discovery)
Mr. Leprince is acting as GLPharma’s interim CEO in addition to his current position of Managing Partner at CTI Life Sciences Fund. Previously, Mr. Leprince was the President and CEO of Aventis Pharma Canada and before served in several management positions in Europe, the Middle East, Africa and France with Marion Merrell Dow, the pharmaceutical subsidiary of The Dow Chemical Company as well as with Hoechst Marion Roussel the pharmaceutical subsidiary of the Hoechst Group.
Mr. Gravel is a Portfolio Manager within the Fonds de solidarité FTQ which he joined in 1997. To date, he has over 30 years of experience in corporate finance and venture capital. Before joining the Fund, Mr. Gravel has been for nearly twenty years employed by a Canadian financial institution leading, in which he held various positions as a financial analyst to director of service Customer and Development for Quebec.
Holds a BBA in Finance from HEC Montreal option, Mr. Gravel has developed throughout his career, a solid expertise in financing public and private companies as well as external funding, which adds distinctive competencies in the field of life sciences.
Dr. Schuetz is a Clinical and Regulatory Consultant with over 15 years of experience leading clinical development programs at both public and privately-held biopharmaceutical companies. Dr. Schuetz was a Venture Partner at OrbiMed Advisors, LLC; he holds a Board position at Relypsa and previously was a member of the Board of Enobia Pharma up until the $1.1 Billion acquisition by Alexion. Dr. Schuetz was previously the CMO of Therion Biologics Corporation and was the Vice President of Clinical Affairs at Transkaryotic Therapies, where he lead the clinical development of Replagal® for the treatment of Fabry disease and Elaprase® for the treatment of Hunter Syndrome.
Dr. Schuetz holds an M.D. degree from Harvard Medical School, cum laude, and a Ph.D. in Genetics from Harvard University. He did an internal medicine residency at Massachusetts General Hospital, where he was also Chief Medical Resident, and a Medical Oncology fellowship at the Dana-Farber Cancer Institute, both in Boston. He is Board Certified in Medical Oncology.
Mike Seckler is currently the General Manager and President of Ferring Canada. Mr. Seckler joined Ferring Pharmaceuticals US in 2003 as National sales Director Infertility. In 2005, he assumed additional responsibility for commercializing Ferring products in the US including launching Endometrin, Euflexxa, and Menopur. Moving to the company’s headquarters in Saint Prex, Switzerland in 2010, to the position of Senior Director, Global Marketing for Ferring’s Reproductive Health franchise, he was instrumental in the company’s 2011 acquisition of Cytokine Pharmasciences Inc. and its subsequent integration into the Ferring organisation. Most recently, he held the role of Senior Director, Global Marketing for Ferring’s Urology and Uro-Oncology franchise. In October 2012, he was appointed as General Manager and President of Ferring Canada. Mr. Seckler has a wealth of international and US management experience gained over 25 years in the pharmaceutical industry. Before joining Ferring, he served in a number of increasingly senior marketing and sales roles in the US for Schering-Plough. Mr. Seckler began his career in pharmaceutical sales with Pfizer Labs.
Mr. Seckler received a Bachelor’s Degree in Health & Human Development from Pennsylvania State University and a MBA also from Pennsylvania State University.